LABORATORY PRODUCTS AND SERVICES
The ULTA™ family of normal flow filtration products is specifically designed to support a wide range of biopharmaceutical liquid filtration applications.
LABORATORY NEWS
-
Valar Labs Announces Validation Of First Histology-Based Test To Predict Response To BCG In Bladder Cancer
Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on Saturday, May 4, 2024 at the 2024 Annual Meeting of the American Urological Association (AUA) as a podium presentation (PD30-03).
- Concert Expands Diagnostic Benefit Program To Manage Laboratory Testing For Health Plans
- Quest Diagnostics To Acquire PathAI Diagnostics To Accelerate AI And Digital Pathology Adoption In Cancer Diagnosis; Forms Licensing Agreements With PathAI
- Lyric And Concert Expand Partnership To Deliver Laboratory Payment Accuracy Solution
- AdvaMed Statement On The Release Of FDA Rule On Laboratory-Developed Tests
ARCHIVED NEWSLETTER
- 04.23.24 -- FDA Warns Industry Of Fraudulent & Unreliable Lab Testing Data In Premarket Submissions
- 04.09.24 -- Pivoting To Allogeneic CAR-T Therapies With Celyad Oncology's CMO, Dr. Charlie Morris
- 03.26.24 -- Notable Public Comments On The FDA's Proposed Regulation For Laboratory Developed Tests
- 03.12.24 -- FDA's CBER Issues Final Guidance For CAR T Cell Products
- 02.27.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
This website uses cookies to ensure you get the best experience on our website. Learn more